ATE499942T1 - 2-methylen-19,21-dinor-1alpha-hydroxy- bishomopregnacalciferol - Google Patents

2-methylen-19,21-dinor-1alpha-hydroxy- bishomopregnacalciferol

Info

Publication number
ATE499942T1
ATE499942T1 AT05849207T AT05849207T ATE499942T1 AT E499942 T1 ATE499942 T1 AT E499942T1 AT 05849207 T AT05849207 T AT 05849207T AT 05849207 T AT05849207 T AT 05849207T AT E499942 T1 ATE499942 T1 AT E499942T1
Authority
AT
Austria
Prior art keywords
hydroxy
bishomopregnacalciferol
dinor
1alpha
methylene
Prior art date
Application number
AT05849207T
Other languages
German (de)
English (en)
Inventor
Hector F Deluca
Lori A Plum
Margaret Clagett-Dame
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Application granted granted Critical
Publication of ATE499942T1 publication Critical patent/ATE499942T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT05849207T 2004-11-22 2005-11-18 2-methylen-19,21-dinor-1alpha-hydroxy- bishomopregnacalciferol ATE499942T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62995804P 2004-11-22 2004-11-22
PCT/US2005/041888 WO2006057915A2 (en) 2004-11-22 2005-11-18 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol

Publications (1)

Publication Number Publication Date
ATE499942T1 true ATE499942T1 (de) 2011-03-15

Family

ID=36498437

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05849207T ATE499942T1 (de) 2004-11-22 2005-11-18 2-methylen-19,21-dinor-1alpha-hydroxy- bishomopregnacalciferol

Country Status (11)

Country Link
US (1) US8604008B2 (cg-RX-API-DMAC7.html)
EP (1) EP1827452B1 (cg-RX-API-DMAC7.html)
JP (1) JP5036548B2 (cg-RX-API-DMAC7.html)
AT (1) ATE499942T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005309820B2 (cg-RX-API-DMAC7.html)
CA (1) CA2588063C (cg-RX-API-DMAC7.html)
DE (1) DE602005026694D1 (cg-RX-API-DMAC7.html)
ES (1) ES2358914T3 (cg-RX-API-DMAC7.html)
MX (1) MX2007006094A (cg-RX-API-DMAC7.html)
NZ (1) NZ555561A (cg-RX-API-DMAC7.html)
WO (1) WO2006057915A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ555561A (en) 2004-11-22 2009-02-28 Wisconsin Alumni Res Found 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol (a Vitamin D derivative)
JP2008520708A (ja) * 2004-11-22 2008-06-19 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１９−ノル−（２０Ｒ）−１α−ヒドロキシ−ビスホモプレグナカルシフェロール
CA2824870C (en) * 2011-06-14 2018-08-14 Wisconsin Alumni Research Foundation 3-desoxy-2-methylene-19-nor-vitamin d analogs and their uses

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666634A (en) * 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
CA2062520C (en) * 1991-03-11 1998-08-11 Hector F. Deluca Synthesis of 1-alpha-hydroxy-secosterol compounds
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
DE69400495T2 (de) 1993-04-05 1997-04-30 Wisconsin Alumni Res Found 19-Nor-vitamin-D3-Verbindung mit einem Substituent an die 2. Stelle
US5552392A (en) * 1993-11-03 1996-09-03 Wisconsin Alumni Research Foundation Method of treating hypoparathyroidism with (20S) vitamin D compounds
US5891865A (en) * 1996-10-04 1999-04-06 Wisconsin Alumni Research Foundation Treatment of arthritic disease induced by infectious agents
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US5945410A (en) 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US5936105A (en) * 1997-06-13 1999-08-10 Tetrionics, Inc. 14-EPI-19-nor-vitamin D compounds and methods
BR0113703A (pt) * 2000-09-08 2003-07-22 Wisconsin Alumni Researcg Foun Compostos e métodos de tratamento de psorìase, leucemia, câncer do cólon, do seio ou da próstata, osteodistrofia renal, de doenças auto-imune, inflamatória e de condição de pele
US6835723B2 (en) * 2001-12-13 2004-12-28 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-1α-hydroxy-bis-homo-pregnacalciferol in crystalline form
US6627622B2 (en) * 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
ES2315426T3 (es) * 2001-12-13 2009-04-01 Wisconsin Alumni Research Foundation (20s)-1alfa-hidroxi-2-metileno-19-nor-bishomopregnacalciferol y sus usos.
US6566352B1 (en) * 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
DE60310050T2 (de) * 2002-03-29 2007-07-05 Wisconsin Alumni Research Foundation, Madison Ein verfahren zur herstellung von 1-alpha-hydroxy-2-methylen-19-nor-homopregnacalciferol
EP1656157B1 (en) * 2003-08-20 2011-12-21 Wisconsin Alumni Research Foundation 2-methylene-19-nor-vitamin d2 compounds
CA2544502A1 (en) 2003-11-25 2005-06-09 Wisconsin Alumni Research Foundation Vitamin d analogs for obesity prevention and treatment
NZ555561A (en) 2004-11-22 2009-02-28 Wisconsin Alumni Res Found 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol (a Vitamin D derivative)
JP2008520708A (ja) * 2004-11-22 2008-06-19 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１９−ノル−（２０Ｒ）−１α−ヒドロキシ−ビスホモプレグナカルシフェロール
NZ555563A (en) * 2004-11-22 2009-02-28 Wisconsin Alumni Res Found 2-methylene-19-nor-(20S)-1alpha-hydroxy-trishomopregnacalciferol
WO2006057899A2 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses
EP2240439B1 (en) * 2007-12-28 2015-03-18 Wisconsin Alumni Research Foundation (20s)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin d analogs
JP2011508744A (ja) * 2007-12-28 2011-03-17 ウィスコンシン アラムナイ リサーチ ファンデーション （２０ｒ）−２３，２３−ジフルオロ−２−メチレン−１９−ノル−ビスホモプレグナカルシフェロール−ビタミンｄ類縁体

Also Published As

Publication number Publication date
WO2006057915A2 (en) 2006-06-01
NZ555561A (en) 2009-02-28
AU2005309820A1 (en) 2006-06-01
CA2588063C (en) 2012-10-16
US20060135800A1 (en) 2006-06-22
JP5036548B2 (ja) 2012-09-26
DE602005026694D1 (de) 2011-04-14
EP1827452A4 (en) 2009-10-21
CA2588063A1 (en) 2006-06-01
EP1827452A2 (en) 2007-09-05
US8604008B2 (en) 2013-12-10
MX2007006094A (es) 2007-07-11
ES2358914T3 (es) 2011-05-16
WO2006057915A3 (en) 2006-07-13
AU2005309820B2 (en) 2011-06-23
JP2008520710A (ja) 2008-06-19
EP1827452B1 (en) 2011-03-02

Similar Documents

Publication Publication Date Title
ATE523487T1 (de) 2-methylen-1-alpha-dihydroxy-19,21-dinor-vitami - d3-analoga und ihre anwendung
WO2008035207A3 (en) 2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof
MX2009004707A (es) Piridina carboxamides como inhibidores 11-beta-hsd1.
CY1110900T1 (el) Χημικες ενωσεις
CY1108275T1 (el) Χημικες ενωσεις
ATE433447T1 (de) Pyrimiidinverbindungen
SE0302811D0 (sv) Novel compounds
PT1902037E (pt) 2,4-diamino-pirimidinas como inibidores de aurora
MX2010002296A (es) Inhibidores iv de polimerasa de fosfadiazina hcv.
SE0401970D0 (sv) Novel compounds
SE0302139D0 (sv) Novel compounds
EA200701707A1 (ru) Пиразолопиримидины
TW200738659A (en) Novel compounds
SE0303541D0 (sv) New compounds
BRPI0519292A2 (pt) compostos orgÂnicos
WO2006119309A3 (en) 19,26,27-TRINOR-1α,25-DIHYDROXYVITAMIN D3 COMPOUNDS
DE50310579D1 (de) Furancarboxamide
ATE554753T1 (de) 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
MX2007006096A (es) 2-metilen-19-nor-(20s)-1a-hidroxi-trishomopregnacalciferol.
WO2006086613A3 (en) 2-METHYLENE-19-NOR- (20S-24S) - 1α, 25-D IHYDROXYVITAMIN-D2
SE0303280D0 (sv) Novel compounds
ATE554774T1 (de) 2-methylen-19-nor-(20s-24epi)-1alpha,25- dihydrovitamin-d2
MX2007006090A (es) 2-metilen-19-nor-(20r)-1a-hidroxi-bishomopregnacalciferol.
DE50311756D1 (de) Mikrobizide oxathiincarboxamide
WO2008125901A3 (en) 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin d3 and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties